Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06541600

Risk Factors for Adverse Outcomes in Sepsis

Sponsor: Qin Zhang

View on ClinicalTrials.gov

Summary

This multi-phase prospective study utilized Data-Independent Acquisition proteomics on a nested subset (15 SIC vs. 15 matched sepsis) to map early molecular alterations. Guided by gene-set enrichment evidence of extracellular matrix (ECM) disruption as a pathway-derived biomarker. Admission matrix metalloproteinase-3 was validated in 567 critically ill patients (417 sepsis, 150 non-septic controls) across three hospital campuses.

Official title: Risk Factors for Adverse Outcomes in Sepsis: a Multi-omics Exploration Based on Clinical Cohort Studies

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

567

Start Date

2017-06-01

Completion Date

2024-10-14

Last Updated

2026-07-28

Healthy Volunteers

No

Conditions

Interventions

DRUG

Ulinastatin

Observational exposure. Ulinastatin was administered intravenously based solely on the attending physicians' clinical judgment during routine care, typically at a dosage of 500,000 U, once daily (qd). It was not assigned by a predefined study protocol.

Locations (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China